Since Bayer and Johnson & Johnson released their joint-effort blood thinning drug Xarelto on the public in 2011, they have seen overwhelming sales growth: the once-a-day blood clot preventative has taken over previous sales leader Pradaxa and completely outpaced rival Eliquis.
A report compiled last month by industry tracker FirstWord Pharma demonstrates just how much Xarelto has overtaken the anticoagulant market though. In the past 12 months, it has grown from $1.6 billion in yearly sales to a now staggering rate of $3.2 billion.
Xarelto’s meteoric rise amounts to a sales growth of just over 95% for the year, and was enough to rank it fourth among all drugs on the market. It also recently ranked 17th for the number of prescriptions filled for the year.
The constant growth in Xarelto use, and that of all three new-generation blood thinners, has some experts dumbfounded. Sure, the new meds appeal to those who want the convenience of no regular blood tests or dietary changes. However, the result of internal bleeding episodes, which can plague all blood thinners, can be catastrophic.
The age-old medication warfarin carries its own bleeding risks for sure. But doctors can also stop it during a crisis with an antidote injection. None of the three new drugs, including Xarelto, have that safety luxury.
The FDA and EMA, Europe’s version, have seen thousands and thousands of internal bleeding reports among patients switching to Xarelto. And worse, more than 1,000 people have died while using the drug.
Right now, a nationwide Xarelto lawsuit is gaining steam against the makers of the drug by those who have been hospitalized with serious bleeding, or by the families of those killed.
This week, a judicial panel will decide whether to combine the cases under one judge to speed up their handling.
This year, Pradaxa maker Boehringer Ingelheim paid out $650 million to patients who suffered similar injuries with their drug. Will the same happen with Xarelto? It’s too soon to tell, but lawyers are urging anyone who’s been hurt by bleeding while on the drug to protect their legal rights.
DrugNews can give you the latest details on the bleeding reports from Xarelto, as well as the current litigation and how to hire a lawyer to file a lawsuit. It costs nothing and only takes a few moments of your time.
Call us today for more details.
Sources:
King, S. FirstWord Lists – Pharma's Fastest Growing Drugs. FirstWord Pharma (November 16, 2014). Retrieved from http://www.firstwordpharma.com/node/1246255#axzz3Jc67HFsp
Helfand, C. Which Old Meds Hold Their Own With Fast-Growing Sovaldi, Tecfidera, and Xarelto? Try Humira and Revlimid. FiercePharma. (November 20, 2014). Retrieved from http://www.fiercepharma.com/story/which-old-meds-hold-their-own-fast-growing-sovaldi-tecfidera-and-xarelto-tr/2014-11-20
Elmiron is a mild blood-thinner drug that has been around since 1996 and is prescribed to treat bladder pain or inflammation, a condition called interstitial cystitis.
Since many of the companies that sold asbestos or used it in their products have long since gone out of business, people who are diagnosed with asbestos-related cancers often think it’s too late to file a lawsuit.
Call, email or live chat with us today to see how we can help.
